Arvinas will discuss 2024 financial results and corporate updates during a live webcast on February 11, 2025.
Quiver AI Summary
Arvinas, Inc., a clinical-stage biotechnology company focused on targeted protein degradation, announced a live webcast for reviewing its fourth quarter and full year 2024 financial results and providing a corporate update on February 11, 2025, at 8:00 a.m. ET. The event will be available on the investor page of Arvinas’ website, with a replay to follow. The company is developing investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders, using its innovative PROTAC® platform to target and degrade harmful proteins. Arvinas is headquartered in New Haven, Connecticut.
Potential Positives
- Arvinas is set to provide a corporate update and review its financial results for Q4 and full year 2024, which can boost investor confidence and transparency.
- The company's progress on multiple investigational drugs targeting critical diseases indicates a strong pipeline and ongoing commitment to innovation in biotechnology.
- The use of the PROTAC® platform highlights Arvinas' unique approach to drug development, potentially positioning the company as a leader in targeted protein degradation therapies.
Potential Negatives
- The announcement includes a live webcast to review financial results, which may indicate there is a need for transparency regarding the company's financial performance, potentially raising concerns among investors.
- The lack of significant positive developments or successful outcomes in the press release could suggest stagnation in the company's progress, which might affect investor confidence.
FAQ
When will Arvinas announce its fourth quarter and full year 2024 financial results?
Arvinas will announce its financial results on Tuesday, February 11, 2025, at 8:00 a.m. ET.
How can I access the live webcast for Arvinas' financial results?
The live webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website.
Will there be a replay of the Arvinas webcast available?
Yes, a replay of the webcast will be available on the Arvinas website following the completion of the event.
What is the focus of Arvinas in drug development?
Arvinas focuses on creating therapies based on targeted protein degradation to treat debilitating and life-threatening diseases.
Where is Arvinas headquartered?
Arvinas is headquartered in New Haven, Connecticut.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- DAVID K LOOMIS (Chief Accounting Officer) sold 231 shares for an estimated $6,396
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 99 institutional investors add shares of $ARVN stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVIDITY PARTNERS MANAGEMENT LP removed 1,490,845 shares (-49.9%) from their portfolio in Q3 2024, for an estimated $36,719,512
- BRAIDWELL LP added 767,242 shares (+148.3%) to their portfolio in Q3 2024, for an estimated $18,897,170
- OPALEYE MANAGEMENT INC. added 700,000 shares (+126.1%) to their portfolio in Q3 2024, for an estimated $17,241,000
- COMMODORE CAPITAL LP removed 684,361 shares (-36.3%) from their portfolio in Q3 2024, for an estimated $16,855,811
- BAKER BROS. ADVISORS LP added 405,576 shares (+inf%) to their portfolio in Q3 2024, for an estimated $9,989,336
- LOGOS GLOBAL MANAGEMENT LP added 400,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $9,852,000
- JPMORGAN CHASE & CO added 367,343 shares (+18.7%) to their portfolio in Q3 2024, for an estimated $9,047,658
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on
LinkedIn
and
X
.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]